MarketsPREMIUM

WATCH: Stock pick — Aspen Pharmacare

Steven Schultz from Momentum talks to Business Day TV about his stock pick of the day

A licensing agreement  between US pharmaceutical manufacturer AbbVie  and  the United Nations’ Medicines Patent Pool will lower the price of HIV/AIDS drugs, including ritonavir,  for children.   Picture: REUTERS/SUKREE SUKPLANG
A licensing agreement between US pharmaceutical manufacturer AbbVie and the United Nations’ Medicines Patent Pool will lower the price of HIV/AIDS drugs, including ritonavir, for children. Picture: REUTERS/SUKREE SUKPLANG

Steven Schultz from Momentum chose Aspen Pharmacare as his stock pick of the day.

“It’s Aspen, it’s a counter that’s effectively halved in value over the past 12 months. There have been a number of reasons why, most notably debt build-up and shareholders are obviously uncomfortable with that.”

Or listen to the full audio:

Subscribe: iono.fm | SpotifyApple PodcastsPocket Casts | Player.fm 

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Comment icon